CD274 and hypophysitis: Hypophysitis incidence is 3.2% for anti-CTLA4 mAbs, 0.4% for anti-PD-1 mAbs, and <0.1% for anti-PD-L1 mAbs, when used as a single agent, and 6.4% for combination therapy.